Drew Rasco

8.3k citations
192 papers · 4.1k · 3 hit papers · h-index 33

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Pancreatic and Hepatic Oncology Research
  • Immunology top 5%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Cancer Immunotherapy and Biomarkers 57
    • Pancreatic and Hepatic Oncology Research 16
    • Cancer Treatment and Pharmacology 15
    • CAR-T cell therapy research 15

Drew Rasco

184 papers receiving 4.1k citations

Drew Rasco's Hit Papers

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ 2021 · 196 citations
1960+2+4Years since publication100200300

Peers

Drew Rasco
Comparison fields: 5 of 101
  • Oncology 2.4k
  • Immunology 870
  • Cancer Research 516
  • Pulmonary and Respiratory Medicine 980
  • Molecular Biology 1.7k
Replace Víctor Moreno with:
Víctor Moreno Spain
Carlos Gomez‐Roca France
Andréa Varga France
Thomas A. Puchalski United States
Dimitrios Bafaloukos Greece
Juanita Lopez United Kingdom
J. Thaddeus Beck United States
Sameek Roychowdhury United States
Silvana Del Vecchio Italy
Ignacio Garrido‐Laguna United States
Drew Rasco relative to Víctor Moreno Spain Víctor Moreno's profile →
Citations per field
00.5×1.7×
Víctor Moreno · 1×
Citations per year

Countries citing papers authored by Drew Rasco

Since Specialization
Citations

This map shows the geographic impact of Drew Rasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Rasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Rasco more than expected).

Fields of papers citing papers by Drew Rasco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Rasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Rasco. The network helps show where Drew Rasco may publish in the future.

Co-authors

The 25 scholars most cited alongside Drew Rasco, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Drew Rasco Line = papers co-authored together Drew Rasco links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 192 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Hit paper breakdown →
2019360
2 2012352
3
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Hit paper breakdown →
2020306
4
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Hit paper breakdown →
2021196
5 2017183
6 2014129
7 2015124
8 2014100
9 201596
10 201989
11 201776
12 201874
13 201370
14 202069
15 201467
16 201966
17 201266
18 202065
19 201364
20 201358

About Drew Rasco

Drew Rasco is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 192 papers that have together received 4.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (57 papers), Monoclonal and Polyclonal Antibodies Research (24 papers), Lung Cancer Treatments and Mutations (17 papers), Pancreatic and Hepatic Oncology Research (16 papers), Chronic Lymphocytic Leukemia Research (16 papers), Cancer Treatment and Pharmacology (15 papers), CAR-T cell therapy research (15 papers) and Cancer Research and Treatments (15 papers). The work is most often cited by research in Oncology (2.4k citations), Immunology (870 citations), Cancer Research (516 citations), Pulmonary and Respiratory Medicine (980 citations) and Molecular Biology (1.7k citations). Drew Rasco has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include Kyriakos P. Papadopoulos, Amita Patnaik, Anthony W. Tolcher, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Vicky Makker, Emmett V. Schmidt, Robert Shumaker and Muralidhar Beeram. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Molecular Cancer Therapeutics and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact